The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible ...

President Donald Trump is attempting to implement a plan to slash drug prices for Americans by more closely aligning their ...

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public ...

A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a new evaluation tool.

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

The third cycle of the drug price negotiations will involve drugs under Medicare Part B. New prices are set to take effect in ...

Medicare seeks public comments as the agency plans to list up to 15 additional drugs selected for the third round of pricing ...

President Trump’s executive order to lower drug prices through cross-agency action left pharma leaders scrambling to make ...

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ ...